Targeting critical needs

Masinova focuses on HIV infection, cancers, and autoimmune diseases—areas where current therapies still face limitations in durability, specificity, and real-world translation. Our programs are built using a rigor-led Quality-by-Design (QbD) framework to generate reproducible, safety-informed data packages and advance candidates efficiently from preclinical development toward clinical readiness.

Our therapeutic areas

We apply modality innovation alongside QbD execution, including:

  • Next-generation engineered T-cell approaches (e.g., CAR T-based strategies) designed to improve specificity, persistence, and resistance to biological failure modes (escape/heterogeneity).

  • Targeted nanomedicine/nanoparticle-enabled concepts intended to improve delivery precision, tissue access, and therapeutic index.

  • Translational decision frameworks linking preclinical endpoints to clinical readiness (biomarkers, safety strategy, and development gates).

HIV infection

Scientific intent

We are developing immune-based therapeutic strategies for HIV aimed at improving control of infection and addressing key biological challenges such as viral diversity, immune escape, and reservoir persistence.

Program readiness

Our HIV program is guided by a comprehensively defined Target Product Profile (TPP), including clear performance goals and measurable translational endpoints.

What partners can expect (under NDA)

A partner-ready package connecting TPP → qualified assays → go/no-go criteria → IND-enabling plan, including safety-by-design considerations and biomarker strategy.

Cancers

Scientific intent

Masinova is advancing early-stage oncology programs for cancers with high unmet need. Our approach prioritizes biological tractability and translational clarity—especially where tumor biology creates barriers such as antigen heterogeneity, tumor microenvironment suppression, and delivery/penetration limitations.

Development approach

We evaluate opportunities where engineered cellular approaches and/or nanomedicine-enabled delivery can improve specificity and durability while controlling safety risk through QbD-defined acceptance criteria and decision gates.

Autoimmune diseases

Scientific intent

We are developing strategies to modulate dysregulated immune responses with the goal of improving disease control while maintaining a strong safety profile. Our program design emphasizes mechanistic rationale, biomarkers for immune activity, and early risk identification.

Development approach

Programs are structured to support reproducibility, safety-by-design, and efficient translation through preclinical milestones, with clinical development planning supported via experienced partners.

Partner with masinova

Masinova welcomes investors, big pharma, and biotech partnership discussions. Confidential program overviews are available under NDA.

Quality-by-design approach

Our Quality-by-Design principles ensure reproducibility, safety, and efficient translation from discovery to preclinical milestones. This rigorous approach sets us apart and accelerates our therapeutic development process.

Investment & partnership

Masinova is actively seeking investors and strategic partners to advance our HIV, cancer, and autoimmune therapy programs. Contact us to learn more about partnering and investment opportunities.